Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.Claudio Vernieri, Mario Giuliano, Gianpiero Rizzo et al.|Journal of Clinical Oncology|2024Cited by 7
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.Claudio Vernieri, Leonardo Provenzano, Maria Vittoria Dieci et al.|Journal of Clinical Oncology|2025Cited by 1